News & Events

Upcoming Events

There are currently no events to display.

Past Events

News Releases

Date Title and Summary
Toggle Summary Celgene and Juno Announce Celgene Exercised Option to Develop and Commercialize CD19-directed Product Candidates
-- $50 million opt-in payment for CD19 program to Juno -- SUMMIT, N.J. & SEATTLE --(BUSINESS WIRE)--Apr. 11, 2016-- Celgene Corporation (NASDAQ: CELG) and Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that Celgene exercised its option to develop and commercialize the Juno CD19 program
Toggle Summary Celgene and Juno Announce Ten-Year Collaboration to Advance Potentially Groundbreaking Immunotherapies for Patients with Cancer and Autoimmune Diseases
Broad strategic collaboration leveraging combined immunology expertise and assets to develop and commercialize novel immunotherapies for the treatment of cancer and autoimmune diseases Celgene gains option to commercialize Juno programs outside North America and co-promote certain programs globally
Toggle Summary CORRECTING and REPLACING JCAR014 Clinical Data Published in Science Translational Medicine: Patients with Advanced Lymphoma in Remission after T-cell Therapy
Patients who received a dose of CD19 targeted defined composition engineered T cells after chemotherapy went into complete remission SEATTLE --(BUSINESS WIRE)--Sep. 7, 2016-- In the contact information of the release, the email address for Christopher Williams should read:
Toggle Summary Court Decides It Lacks Jurisdiction Before FDA Approval Occurs
SEATTLE --(BUSINESS WIRE)--Jun. 14, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, announced today that the U.S. District Court for the District of Delaware decided it lacked jurisdiction at this
Toggle Summary JCAR014 Clinical Data Published in Science Translational Medicine: Patients with Advanced Lymphoma in Remission after T-cell Therapy
Patients who received a dose of CD19 targeted defined composition engineered T cells after chemotherapy went into complete remission SEATTLE --(BUSINESS WIRE)--Sep. 7, 2016-- In a paper published today in Science Translational Medicine , researchers from Fred Hutchinson Cancer Research Center
Toggle Summary Juno Announces Early HSR Clearance for Global Collaboration With Celgene
SEATTLE , Aug. 5, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq:JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today announced that the Federal Trade Commission has granted early termination of the waiting
Toggle Summary Juno Announces FDA Acceptance of Investigational New Drug Application for JCAR017 in Relapsed/Refractory B Cell Non-Hodgkin Lymphoma
SEATTLE , June 29, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq:JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today announced the U.S. Food and Drug Administration ( FDA ) accepted the Company's
Toggle Summary Juno Announces FDA Clearance of Investigational New Drug Application for JCAR015 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia
-- Multi-center, pivotal Phase 2 trial to begin in the near term -- SEATTLE , July 30, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq:JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today announced the U.S.
Toggle Summary Juno Announces New Investments, Leadership Appointments
SEATTLE, Jan. 13, 2014 /PRNewswire-USNewswire/ -- Juno Therapeutics, a new biotechnology company focused on bringing forward novel immunotherapies for cancer, announced today an expanded Series A including Bezos Expeditions, the personal investment company of Jeff Bezos, and leading venture capital
Toggle Summary Juno Appoints Hal Barron, M.D. to Board of Directors
Juno Therapeutics, Inc. today announced the appointment of Hal Barron, M.D., President of Research & Development at Calico, to its Board of Directors “Hal is one of the most respected clinician-scientists and successful drug developers in the biotechnology industry.